No Data
Caribou Biosciences Reports Q3 2024 Financial Results
Caribou Biosciences to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Analysts Are Updating Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Estimates After Its Third-Quarter Results
Caribou Biosciences' Strategic Advancements and Financial Efficiency Bolster Buy Rating